Immuneering Corp (IMRX) - Total Liabilities
Based on the latest financial reports, Immuneering Corp (IMRX) has total liabilities worth $13.08 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Immuneering Corp - Total Liabilities Trend (2019–2024)
This chart illustrates how Immuneering Corp's total liabilities have evolved over time, based on quarterly financial data. See Immuneering Corp (IMRX) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Immuneering Corp Competitors by Total Liabilities
The table below lists competitors of Immuneering Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
First Western Financial Inc
NASDAQ:MYFW
|
USA | $2.97 Billion |
|
Lingnan Landscape Co Ltd
SHE:002717
|
China | CN¥12.61 Billion |
|
Samyang Cor
KO:145990
|
Korea | ₩1.84 Trillion |
|
Brooge Holdings Ltd
NASDAQ:BROG
|
USA | $429.22 Million |
|
Synopex Inc
KQ:025320
|
Korea | ₩90.38 Billion |
|
Dishman Carbogen Amcis Limited
NSE:DCAL
|
India | Rs47.44 Billion |
|
Chlitina Holding Ltd
TW:4137
|
Taiwan | NT$4.24 Billion |
|
Ananti Inc
KQ:025980
|
Korea | ₩832.68 Billion |
Liability Composition Analysis (2019–2024)
This chart breaks down Immuneering Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Immuneering Corp.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 24.00 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Immuneering Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Immuneering Corp (2019–2024)
The table below shows the annual total liabilities of Immuneering Corp from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $11.33 Million | -5.66% |
| 2023-12-31 | $12.01 Million | -4.06% |
| 2022-12-31 | $12.52 Million | +16.71% |
| 2021-12-31 | $10.72 Million | -82.39% |
| 2020-12-31 | $60.90 Million | +195.27% |
| 2019-12-31 | $20.63 Million | -- |
About Immuneering Corp
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 … Read more